These Two Oncology Drugs Are Key To Roche’s Future Growth


Roche’s Oncology business accounts for over 50% of the company valuation, according to our estimates. The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan, as these three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016.December 13, 2017 at 01:33PM

via Forbes Real Time http://ift.tt/2C1cfno